Clinical Trial Update: Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis [Phase 2]

View source ↗

Summary

Phase 2 trial investigating MT-9938 for uremic pruritus in end-stage renal disease patients on hemodialysis was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Uremic Pruritus

Drugs mentioned

• MT-9938

Snippet

Sponsor: Toray Industries, Inc | Conditions: Uremic Pruritus | Phase 2 | Status: TERMINATED | Results posted: 2022-02-09